LOGIN  |  REGISTER
Cue Biopharma
Amneal Pharmaceuticals

Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call

February 21, 2023 | Last Trade: US$120.96 5.77 -4.55

AUSTIN, Texas / Feb 21, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).

Earnings Conference Call Information:

Event:

 

Natera’s Fourth Quarter and Year-End 2022 Financial Results

Date:

 

Tuesday, Feb. 28, 2023

Time:

 

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

 

1 (888) 770-7321, Domestic

 

 

1 (929) 201-7107, International

Conference ID:

 

7684785

Webcast:

 

https://events.q4inc.com/attendee/196748198

A webcast replay will be available at investor.natera.com.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Assertio

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB